236 related articles for article (PubMed ID: 21077160)
1. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
[TBL] [Abstract][Full Text] [Related]
2. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
3. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
[TBL] [Abstract][Full Text] [Related]
4. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
[TBL] [Abstract][Full Text] [Related]
5. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
[TBL] [Abstract][Full Text] [Related]
6. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
7. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
[TBL] [Abstract][Full Text] [Related]
8. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
Mladenov R; Hristodorov D; Cremer C; Hein L; Kreutzer F; Stroisch T; Niesen J; Brehm H; Blume T; Brümmendorf TH; Jost E; Thepen T; Fischer R; Stockmeyer B; Barth S; Stein C
Int J Cancer; 2015 Dec; 137(11):2729-38. PubMed ID: 26041304
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
[TBL] [Abstract][Full Text] [Related]
10. A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro.
Zhu X; Tao K; Li Y; Li S; Zhang L; Wang D; Zhong L; Feng W
Immunol Lett; 2013; 154(1-2):18-24. PubMed ID: 23954809
[TBL] [Abstract][Full Text] [Related]
11. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
12. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
Matthey B; Engert A; Barth S
Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
[TBL] [Abstract][Full Text] [Related]
14. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
[TBL] [Abstract][Full Text] [Related]
15. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
[TBL] [Abstract][Full Text] [Related]
16. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
[TBL] [Abstract][Full Text] [Related]
17. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
[TBL] [Abstract][Full Text] [Related]
18. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
19. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
[TBL] [Abstract][Full Text] [Related]
20. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]